Catalyst Wire Dossier Catalyst Wire Dossier

Lentiviral vector gene therapy for beta-thalassemia

· Institute of Hematology & Blood Diseases Hospital, China
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Lentiviral vector gene therapy for beta-thalassemia, covering 2025-08-05 to 2025-08-05. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients [NA]

See pricing